The biotech firm cites expanding demand and telehealth launches for its raised full-year revenue guidance.
Arcutis Biotherapeutics raised its 2026 net revenue guidance to $525M-$540M, up from prior projections. The increase reflects stronger demand for its topical treatment ZORYVE and recent telehealth initiatives, management said during the Q2 2026 earnings call.
The company previously reported revenue growth driven by ZORYVE adoption, though exact prior guidance figures were not disclosed. Expansion into telehealth aims to broaden patient access and accelerate prescription volumes.
Shares of ARQT showed limited movement following the announcement, as investors await further pipeline updates.